Vaccines - Southeast Asia

Southeast Asia

Highlights

In Southeast Asia, the Vaccines market is anticipated to witness a significant rise in revenue, projected to reach US$2.33bn by 2024.
This growth is further expected to exhibit a promising annual growth rate (CAGR 2024-2029) of -6.56%, leading to a market volume of US$1.66bn by 2029.
When compared globally, United States is projected to generate the highest revenue in the Vaccines market, amounting to US$29.12bn in 2024.
In Southeast Asia, the demand for vaccines has surged as countries prioritize public health and aim to achieve widespread immunization.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for vaccines in Southeast Asia has been on the rise in recent years due to various factors.

Customer preferences: Customers in Southeast Asia have become more aware of the importance of vaccines in preventing diseases. There has been an increase in demand for vaccines for both children and adults. In addition, the COVID-19 pandemic has led to a surge in demand for vaccines, with many countries in the region rolling out vaccination programs.

Trends in the market: The vaccines market in Southeast Asia is diverse and rapidly evolving. Countries such as Indonesia, Vietnam, and the Philippines have seen significant growth in the market, driven by an increase in government spending on healthcare and rising incomes. The market is dominated by multinational pharmaceutical companies, but there has been a rise in local players entering the market. In addition, there has been a shift towards more innovative vaccines, such as those for dengue fever and HPV.

Local special circumstances: Each country in Southeast Asia has its own unique circumstances that affect the vaccines market. For example, Indonesia has a large population and a high burden of disease, which has led to a focus on vaccines for diseases such as measles and polio. In contrast, Singapore has a highly developed healthcare system and a focus on preventative healthcare, which has led to a high uptake of vaccines for both children and adults.

Underlying macroeconomic factors: Several macroeconomic factors are driving the growth of the vaccines market in Southeast Asia. These include rising incomes, population growth, and increasing government spending on healthcare. In addition, the COVID-19 pandemic has led to a surge in demand for vaccines and an increase in government spending on healthcare across the region. However, there are also challenges facing the market, such as regulatory barriers and a lack of infrastructure in some countries. In conclusion, the vaccines market in Southeast Asia is growing rapidly, driven by rising demand for vaccines and underlying macroeconomic factors. While each country in the region has its own unique circumstances, there are also common trends such as a focus on innovative vaccines and a rise in local players entering the market. The market is likely to continue to evolve in the coming years, driven by factors such as population growth, rising incomes, and increasing government spending on healthcare.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.